Skip to content

Released Aug 5, 2020, after the close

10-Q filed Aug 5, 2020, 36 days after period end · 0001564590-20-036806

Q2 2020 · 10-Q
Revenue$5.47M+94.0% vs Q2 2019+117.3% vs Q1 2020
Net Income-$28.07MN/M vs Q2 2019N/M vs Q1 2020
EPS Diluted-$0.35N/M vs Q2 2019N/M vs Q1 2020
Operating Income-$28,707,000N/M
Operating Cash Flowderived$38,841,000N/M
Free Cash Flowderived$38,205,000N/M
Margins · derived
Operating margin-525.3%+329.7 pt vs Q2 2019
Net margin-513.7%+319.8 pt vs Q2 2019

What the release said

The release

Same quarter

MetricQ2 2020Q2 2019Q2 2018Q2 2017
Revenue$5.47M$2.82M$1.03M$1.03M
Net Income-$28.07M-$23.48M-$19.65M-$9.65M
EPS Diluted-$0.35-$0.36-$0.37-$0.23

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR